Tapewire

Nasdaq · USD

ANTX

AN2 Therapeutics, Inc.

Export transactions ↓
Tapewire entity
1085
SEC CIK
0001880438
Parsed reports
215

Last 12 months

Inside the activity.

1 purchase rows · 22 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202502
Dec 202500
Jan 202608
Feb 202600
Mar 202601
Apr 202600
May 202601
Jun 202600
Jul 202601
Aug 202602
Sep 202617
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 12, 2026 Filed Oct 13, 2026 21:13 UTC GrantCommon Stock 2,283 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-420643 · ownership.xml · nonDerivative · entry 1

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,156

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
October 12, 2026 Filed Oct 13, 2026 21:12 UTC GrantCommon Stock 389 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-420641 · ownership.xml · nonDerivative · entry 1

Martin Patricia A. · CIK 0001916764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,252

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
October 12, 2026 Filed Oct 13, 2026 21:12 UTC
Aziz KabeerDirector
GrantCommon Stock 2,465 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-420639 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,571

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
September 15, 2026 Filed Sep 16, 2026 21:35 UTC
Trenor Cameron C. IIIChief Medical Officer
GrantStock Option (right to by) · Derivative 233,333 $0.00 Strike: $5.36 $0.00
Disclosure

SEC source: 0001193125-26-393274 · ownership.xml · derivative · entry 2

Trenor Cameron C. III · CIK 0002150478 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,333

Underlying: Common Stock · 233,333 shares

Expires 2036-09-14

F2 · derivative.exercise_date: The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
September 15, 2026 Filed Sep 16, 2026 21:35 UTC
Trenor Cameron C. IIIChief Medical Officer
GrantCommon Stock 116,667 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-393274 · ownership.xml · nonDerivative · entry 1

Trenor Cameron C. III · CIK 0002150478 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,667

F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
September 09, 2026 Filed Sep 11, 2026 23:45 UTC SaleCommon Stock 585 $6.02 $3,524.22
Disclosure

SEC source: 0001193125-26-389545 · ownership.xml · nonDerivative · entry 2

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 624,765

F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F6 · ownership.nature: Shares held directly by MGC 2018 QP.

Read SEC document
September 09, 2026 Filed Sep 11, 2026 23:45 UTC SaleCommon Stock 523 $6.02 $3,150.71
Disclosure

SEC source: 0001193125-26-389545 · ownership.xml · nonDerivative · entry 1

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 557,467

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F5 · ownership.nature: Shares held directly by MGC 2018 LP.

Read SEC document
September 08, 2026 Filed Sep 8, 2026 23:42 UTC SaleCommon Stock 5,294 $6.02 $31,860.88
Disclosure

SEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 4

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 625,350

F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F6 · ownership.nature: Shares held directly by MGC 2018 QP.

Read SEC document
September 08, 2026 Filed Sep 8, 2026 23:42 UTC SaleCommon Stock 4,725 $6.02 $28,436.47
Disclosure

SEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 3

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 557,990

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F5 · ownership.nature: Shares held directly by MGC 2018 LP.

Read SEC document
September 03, 2026 Filed Sep 8, 2026 23:42 UTC SaleCommon Stock 3,223 $6.07 $19,562.97
Disclosure

SEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 2

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 630,644

F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F6 · ownership.nature: Shares held directly by MGC 2018 QP.

Read SEC document
September 03, 2026 Filed Sep 8, 2026 23:42 UTC SaleCommon Stock 2,877 $6.07 $17,462.81
Disclosure

SEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 1

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 562,715

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F5 · ownership.nature: Shares held directly by MGC 2018 LP.

Read SEC document
September 01, 2026 Filed Sep 4, 2026 20:25 UTC
Williams Sarah JoannePrincipal Accounting Officer
SaleCommon Stock 272 $5.53 $1,504.16
Disclosure

SEC source: 0001193125-26-383697 · ownership.xml · nonDerivative · entry 1

Williams Sarah Joanne · CIK 0002108922 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,311

F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026.

F2 · balance_after: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.

Read SEC document
September 01, 2026 Filed Sep 2, 2026 22:43 UTC PurchaseCommon Stock 2,098 $5.53 $11,601.94
Disclosure

SEC source: 0001193125-26-380595 · ownership.xml · nonDerivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,708

Read SEC document
August 17, 2026 Filed Aug 19, 2026 21:58 UTC SaleCommon Stock 18,706 $6.01 $112,389.39
Disclosure

SEC source: 0001193125-26-357225 · ownership.xml · nonDerivative · entry 2

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 633,867

F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F6 · ownership.nature: Shares held directly by MGC 2018 QP.

Read SEC document
August 17, 2026 Filed Aug 19, 2026 21:58 UTC SaleCommon Stock 16,696 $6.01 $100,312.91
Disclosure

SEC source: 0001193125-26-357225 · ownership.xml · nonDerivative · entry 1

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 565,592

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F5 · ownership.nature: Shares held directly by MGC 2018 LP.

Read SEC document
August 14, 2026 Filed Aug 14, 2026 18:12 UTC GiftCommon Stock 405,880 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-351801 · ownership.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Reflects a gift of shares to the children of the Reporting Person.

F2 · ownership.nature: The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.

Read SEC document
July 10, 2026 Filed Jul 10, 2026 23:41 UTC
Aziz KabeerDirector
GrantCommon Stock 2,852 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-301167 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,106

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
July 10, 2026 Filed Jul 10, 2026 23:41 UTC GrantCommon Stock 2,789 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-301166 · ownership.xml · nonDerivative · entry 1

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,873

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
July 10, 2026 Filed Jul 10, 2026 23:40 UTC GrantCommon Stock 766 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-301165 · ownership.xml · nonDerivative · entry 1

Martin Patricia A. · CIK 0001916764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,863

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 18:15 UTC
Eizen Joshua MSee Remarks
SaleCommon Stock 5,945 $4.17 $24,802.54
Disclosure

SEC source: 0001193125-26-301092 · ownership.xml · nonDerivative · entry 1

Eizen Joshua M · CIK 0001949621 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,554

F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026.

F2 · balance_after: Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.

F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:31 UTC
Williams Sarah JoannePrincipal Accounting Officer
SaleCommon Stock 265 $4.43 $1,173.95
Disclosure

SEC source: 0001193125-26-253622 · ownership.xml · nonDerivative · entry 1

Williams Sarah Joanne · CIK 0002108922 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,583

F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on May 29, 2026.

F2 · balance_after: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,766 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.

Read SEC document
April 10, 2026 Filed Apr 11, 2026 00:58 UTC
Aziz KabeerDirector
GrantCommon Stock 3,775 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-151632 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,254

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
April 10, 2026 Filed Apr 11, 2026 00:53 UTC GrantCommon Stock 3,775 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-151628 · ownership.xml · nonDerivative · entry 1

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,084

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
April 10, 2026 Filed Apr 11, 2026 00:51 UTC GrantCommon Stock 1,192 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-151626 · ownership.xml · nonDerivative · entry 1

Martin Patricia A. · CIK 0001916764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,097

F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 19:06 UTC
Eizen Joshua MSee Remarks
Disposition to issuerStock Option (right to buy) · Derivative 50,150 Not disclosed Strike: $14.29 Not disclosed
Disclosure

SEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 4

Eizen Joshua M · CIK 0001949621 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,150 shares

Expires 2033-02-14

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 19:06 UTC
Eizen Joshua MSee Remarks
GrantStock Option (right to buy) · Derivative 50,150 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 3

Eizen Joshua M · CIK 0001949621 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,150

Underlying: Common Stock · 50,150 shares

Expires 2033-02-14

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 19:06 UTC
Eizen Joshua MSee Remarks
Disposition to issuerStock Option (right to buy) · Derivative 92,000 Not disclosed Strike: $17.88 Not disclosed
Disclosure

SEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 2

Eizen Joshua M · CIK 0001949621 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 92,000 shares

Expires 2032-10-13

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 19:06 UTC
Eizen Joshua MSee Remarks
GrantStock Option (right to buy) · Derivative 92,000 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120210 · ownership.xml · derivative · entry 1

Eizen Joshua M · CIK 0001949621 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,000

Underlying: Common Stock · 92,000 shares

Expires 2032-10-13

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Chanda SanjayChief Development Officer
Disposition to issuerStock Option (right to buy) · Derivative 41,665 Not disclosed Strike: $6.60 Not disclosed
Disclosure

SEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 6

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 41,665 shares

Expires 2031-04-29

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Chanda SanjayChief Development Officer
GrantStock Option (right to buy) · Derivative 41,665 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 5

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,665

Underlying: Common Stock · 41,665 shares

Expires 2031-04-29

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Chanda SanjayChief Development Officer
Disposition to issuerStock Option (right to buy) · Derivative 57,950 Not disclosed Strike: $14.29 Not disclosed
Disclosure

SEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 4

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 57,950 shares

Expires 2033-02-14

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Chanda SanjayChief Development Officer
GrantStock Option (right to buy) · Derivative 57,950 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 3

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,950

Underlying: Common Stock · 57,950 shares

Expires 2033-02-14

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Chanda SanjayChief Development Officer
Disposition to issuerStock Option (right to buy) · Derivative 66,000 Not disclosed Strike: $17.28 Not disclosed
Disclosure

SEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 2

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,000 shares

Expires 2032-05-11

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Chanda SanjayChief Development Officer
GrantStock Option (right to buy) · Derivative 66,000 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 1

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,000

Underlying: Common Stock · 66,000 shares

Expires 2032-05-11

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Day LucyChief Financial Officer
Disposition to issuerStock Option (right to buy) · Derivative 82,300 Not disclosed Strike: $14.29 Not disclosed
Disclosure

SEC source: 0001193125-26-120236 · ownership.xml · derivative · entry 6

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 82,300 shares

Expires 2033-02-14

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Day LucyChief Financial Officer
GrantStock Option (right to buy) · Derivative 82,300 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120236 · ownership.xml · derivative · entry 5

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,300

Underlying: Common Stock · 82,300 shares

Expires 2033-02-14

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Day LucyChief Financial Officer
Disposition to issuerStock Option (right to buy) · Derivative 66,000 Not disclosed Strike: $17.28 Not disclosed
Disclosure

SEC source: 0001193125-26-120236 · ownership.xml · derivative · entry 4

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,000 shares

Expires 2032-05-11

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Day LucyChief Financial Officer
GrantStock Option (right to buy) · Derivative 66,000 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120236 · ownership.xml · derivative · entry 3

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,000

Underlying: Common Stock · 66,000 shares

Expires 2032-05-11

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Day LucyChief Financial Officer
Disposition to issuerStock Option (right to buy) · Derivative 73,665 Not disclosed Strike: $6.60 Not disclosed
Disclosure

SEC source: 0001193125-26-120236 · ownership.xml · derivative · entry 2

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73,665 shares

Expires 2031-04-29

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:16 UTC
Day LucyChief Financial Officer
GrantStock Option (right to buy) · Derivative 73,665 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120236 · ownership.xml · derivative · entry 1

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,665

Underlying: Common Stock · 73,665 shares

Expires 2031-04-29

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:13 UTC Disposition to issuerStock Option (right to buy) · Derivative 23,742 Not disclosed Strike: $5.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120230 · ownership.xml · derivative · entry 6

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:13 UTC GrantStock Option (right to buy) · Derivative 23,742 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120230 · ownership.xml · derivative · entry 5

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:13 UTC Disposition to issuerStock Option (right to buy) · Derivative 10,362 Not disclosed Strike: $17.28 Not disclosed
Disclosure

SEC source: 0001193125-26-120230 · ownership.xml · derivative · entry 4

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,362 shares

Expires 2032-05-11

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:13 UTC GrantStock Option (right to buy) · Derivative 10,362 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120230 · ownership.xml · derivative · entry 3

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,362

Underlying: Common Stock · 10,362 shares

Expires 2032-05-11

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:13 UTC Disposition to issuerStock Option (right to buy) · Derivative 10,665 Not disclosed Strike: $6.60 Not disclosed
Disclosure

SEC source: 0001193125-26-120230 · ownership.xml · derivative · entry 2

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,665 shares

Expires 2031-04-29

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:13 UTC GrantStock Option (right to buy) · Derivative 10,665 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120230 · ownership.xml · derivative · entry 1

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,665

Underlying: Common Stock · 10,665 shares

Expires 2031-04-29

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:11 UTC
Aziz KabeerDirector
Disposition to issuerStock Option (right to buy) · Derivative 23,742 Not disclosed Strike: $5.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 4

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:11 UTC
Aziz KabeerDirector
GrantStock Option (right to buy) · Derivative 23,742 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 3

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:11 UTC
Aziz KabeerDirector
Disposition to issuerStock Option (right to buy) · Derivative 20,724 Not disclosed Strike: $17.28 Not disclosed
Disclosure

SEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,724 shares

Expires 2032-05-11

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:11 UTC
Aziz KabeerDirector
GrantStock Option (right to buy) · Derivative 20,724 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,724

Underlying: Common Stock · 20,724 shares

Expires 2032-05-11

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.